Low-Dose Involved-Field Radiotherapy as Alternative Treatment of Nodular Lymphocyte Predominance Hodgkin's Lymphoma

• Published in: International journal of radiation oncology, biology, physics Vol. 74; no. 4; pp. 1199 - 1202
• Main Authors: Haas, Rick L.M., M.D., Ph.D, Girinsky, Theo, M.D., Ph.D, Aleman, Berthe M.P., M.D., Ph.D, Henry-Amar, Michel, M.D., Ph.D, de Boer, Jan-Paul, M.D., Ph.D, de Jong, Daphne, M.D., Ph.D
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.07.2009
• Subjects: Adolescent; Adult; Female; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Hodgkin Disease - pathology; Hodgkin Disease - radiotherapy; Humans; LYMPHOCYTES; LYMPHOMAS; Male; Middle Aged; PATIENTS; RADIATION DOSES; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; RADIOTHERAPY; Radiotherapy Dosage; Recurrence; Remission Induction; TOXICITY; Young Adult
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2008.09.049

Purpose Nodular lymphocyte predominance Hodgkin's lymphoma is a very rare disease, characterized by an indolent clinical course, with sometimes very late relapses occurring in a minority of all patients. Considerable discussion is ongoing on the treatment of primary and relapsed disease. Patients and Methods A group of 9 patients were irradiated to a dose of 4 Gy on involved areas only. Results After a median follow-up of 37 months (range, 6–66), the overall response rate was 89%. Six patients had complete remission (67%), two had partial remission (22%), and one had stable disease (11%). Of 8 patients, 5 developed local relapse 9–57 months after radiotherapy. No toxicity was noted. Conclusion In nodular lymphocyte predominance Hodgkin's lymphoma, low-dose radiotherapy provided excellent response rates and lasting remissions without significant toxicity.